Berbamine Enhances the Efficacy of Gefitinib by Suppressing STAT3 Signaling in Pancreatic Cancer Cells

BACKGROUND: Small molecular inhibitors such as gefitinib (Gefi), which target EGF receptor (EGFR), are considered to be a viable pathway for the selective inhibition of pancreatic cancer (PC) development. However, the large difference in Gefi response between PC patient individuals and PC cell lines...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Bingren, Cai, Huajie, Yang, Shouzhang, Tu, Jinfu, Huang, Xiaming, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935307/
https://www.ncbi.nlm.nih.gov/pubmed/31920333
http://dx.doi.org/10.2147/OTT.S223242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935307/
https://www.ncbi.nlm.nih.gov/pubmed/31920333
http://dx.doi.org/10.2147/OTT.S223242

Ejemplares similares